RE:RE:RE:RE:RE:FDA decision will have waterfall effect on other companiesIs this scientific report considered a paid article too? Again just a quick google search, there's more out there. Whether you like it or not PMN310 clinical investment will progress much faster if aducanumab is approved even with lots of conditions. We can't undo all the comparisons done in the past, so now we have to hope that aducanumab gets approved. The Biogen approval will create many billions in Biotech industry and a new hope for Alzheimer's research.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614461/ M101 wrote: Ouch! Paid content from Promis doesn't count as an article.
This scenario was so completely contrived by our consultants. These bozos could have gone the opposite direction by forecasting Aducanumab's failure and then we'd be in a win-win situation regardless of the FDA panel review. They chose instead to put our money into an excuse for their promotional failures, and now you're playing into their game.